Inside every stressed cell, a quiet emergency response unfolds. When oxygen runs low, toxins accumulate, or nutrients grow scarce, mammalian cells assemble temporary structures known as stress granules, non-membranous aggregates of proteins and RNA that condense in the cytoplasm. In healthy tissue, these assemblies act as a protective pause button, halting protein production so the cell can weather the storm and resume normal function once conditions improve. But a new study suggests that in oral squamous cell carcinoma, one of the most common and disfiguring malignancies of the head and neck, this ancient survival machinery may be hijacked to serve a darker purpose: helping tumors grow and spread.

The research, conducted by a team at Kangwon National University in South Korea and published in Cell Death Discovery, examined how stress granule formation influences tumor progression and metastasis in oral squamous cell carcinoma, or OSCC. The findings point to a specific molecular switch, the phosphorylation of a protein called eIF2α, as a central driver of the process. When that switch is suppressed, the study reports, stress granule formation drops, and with it the growth and metastatic burden of tumors in mouse models. The work adds oral cancer to a growing list of malignancies in which the integrated stress response appears to fuel, rather than restrain, disease.

To understand why this matters, it helps to consider what stress granules actually do. Under stress, cells activate kinases that phosphorylate eIF2α, the alpha subunit of a translation initiation factor. Phosphorylated eIF2α dampens global protein synthesis, and the messenger RNAs that would otherwise be translated are instead sequestered, along with RNA-binding proteins, into dense cytoplasmic droplets. Key markers of these structures include G3BP1, TIAR, and PABP, proteins that researchers use to identify stress granules under the microscope. In normal cells, this translational arrest conserves energy and prevents the accumulation of damaged or misfolded proteins. The system is meant to be reversible: when the stress passes, the granules dissolve and translation restarts.

Cancer cells, however, live in a state of chronic stress. Tumors outgrow their blood supply, creating regions of hypoxia, low oxygen tension that would kill most normal cells. They also face nutrient deprivation, acidic microenvironments, and assault from chemotherapy and radiation. In this context, the stress response can become a liability for the patient rather than a safeguard for the cell. Previous work in other cancers has implicated stress granules in tumor progression and metastasis, partly through their interactions with key signaling pathways, but their role in oral squamous cell carcinoma had remained poorly understood, despite growing scientific interest in the topic.

The Korean team began by comparing human tumor tissue with adjacent normal tissue. They found that markers of stress granules, including G3BP1, eIF2α, TIAR, and PABP, were significantly overexpressed in OSCC tissues compared with their normal counterparts. This observation established that the stress granule machinery is not merely present in oral cancer but is amplified, suggesting that tumor cells may rely on it more heavily than the healthy cells around them. Overexpression of these markers alone does not prove causation, but it set the stage for the functional experiments that followed.

Those experiments turned to mouse models built from OSCC cells that had been preconditioned with hypoxia, deliberately exposing the cells to low oxygen before implantation. The logic was to mimic the stressful conditions tumor cells encounter in a real growing tumor and to ask whether cells that had already mounted a stress response behaved differently afterward. In parallel, the researchers used a compound called ISRIB, an inhibitor of the integrated stress response that acts downstream of eIF2α phosphorylation, in mice subjected to sodium arsenite-induced stress. Sodium arsenite is a classic laboratory trigger of oxidative stress and a reliable inducer of stress granule formation, making it a useful tool for probing the pathway.

The results were striking. In both experimental settings, suppression of eIF2α phosphorylation was associated with reduced stress granule formation, reduced tumor growth, and a reduced metastatic burden. In other words, when the researchers blocked the molecular event that nucleates stress granules, the tumors not only grew more slowly but also spread less aggressively. Conversely, the study found that stress granule formation was elevated during hypoxia-induced stress, underscoring a stress-responsive regulatory mechanism in which the harsh conditions of the tumor microenvironment actively promote the assembly of these granules. Together, the data sketch a coherent chain of causation: hypoxia and other stresses trigger eIF2α phosphorylation, phosphorylation drives stress granule assembly, and the granules support the cellular programs that allow OSCC cells to proliferate and colonize distant sites.

Why would a structure designed to protect cells become an engine of metastasis? The authors and other researchers in the field point to the selective nature of stress granules. While global translation is arrested, certain messenger RNAs are preferentially stored within the granules and protected from degradation. Among the transcripts sheltered this way are often those encoding proteins that promote survival, invasion, and epithelial-to-mesenchymal transition, the process by which stationary epithelial cancer cells acquire the motility needed to invade surrounding tissue and enter the bloodstream. By acting as temporary warehouses for pro-metastatic messages, stress granules may allow tumor cells to stockpile the tools of aggression, releasing them for translation once the acute stress subsides. In this view, the granule is not merely a damage-control structure but a staging ground for the next phase of tumor progression.

The therapeutic implications are considerable. Oral squamous cell carcinoma is frequently diagnosed at advanced stages, and metastasis to cervical lymph nodes is one of the strongest predictors of poor outcome. Existing treatments, surgery, radiation, and chemotherapy, remain limited in their ability to control disseminated disease. If stress granule formation genuinely drives metastatic behavior, then the pathway offers a new target. ISRIB, the compound used in the mouse experiments, has attracted attention in recent years for its ability to blunt the integrated stress response, and the new findings suggest that agents with a similar mechanism could be explored as anti-metastatic therapies in oral cancer. The authors conclude that stress granules promote OSCC progression via eIF2α phosphorylation and might serve as a novel therapeutic target, a formulation that is deliberately cautious but clinically suggestive.

As with any preclinical study, important caveats apply. The evidence comes from human tissue comparisons and mouse models, and translating these findings into patients will require further work to confirm that the same mechanism operates in human tumors in real time, to identify which patient subsets have the highest stress granule activity, and to develop inhibitors with acceptable safety profiles. Suppressing a fundamental cellular stress pathway carries risks, since normal tissues also rely on the integrated stress response during injury and inflammation. Still, the study fills a genuine gap in the literature by connecting a well-characterized cellular stress mechanism to one of the most clinically feared behaviors of oral cancer. It also adds to a broader shift in cancer biology: the recognition that tumors are not just collections of mutated genes but ecosystems shaped by physical and chemical stress, and that the survival programs cells use to endure hardship can be turned against the organism that hosts them. For patients with oral squamous cell carcinoma, whose disease too often spreads before it can be stopped, the humble stress granule may prove to be an unexpected and consequential adversary.

Subject of Research: The role of stress-induced eIF2α phosphorylation and stress granule formation in promoting metastasis of oral squamous cell carcinoma

Article Title: Stress-induced eIF2α phosphorylation promotes tumor metastasis in oral squamous cell carcinoma

Article References: Kim, S., Park, S., Lee, Y., Park, G., & Choi, J. (2026). Stress-induced eIF2α phosphorylation promotes tumor metastasis in oral squamous cell carcinoma. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03412-4

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03412-4

Keywords: stress granules, eIF2α phosphorylation, oral squamous cell carcinoma, metastasis, integrated stress response, ISRIB, hypoxia, G3BP1, tumor progression, translational arrest, cancer biology, therapeutic target

In the ongoing battle against prostate cancer, one of the most formidable obstacles researchers and clinicians face is the cancer cells’ remarkable ability to develop resistance to treatments. These malignant cells employ sophisticated adaptive mechanisms to survive the onslaught of therapeutic agents, rendering many promising drugs less effective over time. A groundbreaking study led by Dr. Noel Warfel and his team at the MUSC Hollings Cancer Center has uncovered a hitherto unrecognized pathway that explains why certain protein-targeting drugs falter, offering fresh hope for more potent and durable therapies. Published in the latest issue of Cancer Letters, this research not only elucidates a novel survival mechanism in prostate cancer cells but also proposes an innovative therapeutic strategy to circumvent drug resistance.

At the heart of this discovery lies PIM1, a serine/threonine kinase well-known for its role in promoting prostate tumor growth, survival, and resistance to conventional therapies. Despite the development of various PIM1 inhibitors aimed at curbing its kinase activity, clinical success has been elusive, particularly in patients with solid tumors. The study probes the inadequacies of these conventional inhibitors and shifts the focus towards understanding the multifaceted biology of PIM1. Dr. Warfel’s work reveals that simply inhibiting PIM1’s enzymatic function does not fully neutralize its cancer-supporting properties, as the protein wields influence beyond its traditional kinase signaling.

Classically, kinase inhibitors designed to target PIM1 have been intended to block its enzymatic activity—effectively halting the phosphorylation events that drive tumor progression. However, Warfel’s team discovered that these drugs paradoxically cause an accumulation of PIM1 protein within cancer cells. Rather than being degraded, the surplus protein lingers and continues to facilitate cancer cell survival through kinase-independent mechanisms. This phenomenon results in a paradoxical biological double-edged sword: while inhibiting the enzyme’s catalytic function, the drugs inadvertently empower cancer cells with a fresh lifeline to resist death.

Key to this newly uncovered survival mechanism is the interaction between PIM1 and another protein known as HMGB1, a chromatin-binding factor usually confined to the nucleus. HMGB1 has a pivotal role in orchestrating cellular responses to DNA damage, but when PIM1 protein is abundant, these two form a complex that relocates HMGB1 from the nucleus to the cytoplasm. Once in the cytoplasm, HMGB1 ignites autophagy—a cellular recycling process that allows cancer cells to eliminate dysfunctional organelles, particularly damaged mitochondria.

Damaged mitochondria are notorious sources of reactive oxygen species and oxidative stress, conditions that can precipitate cell death. By facilitating the clearance of these harmful mitochondria, the PIM1-HMGB1 axis effectively lowers oxidative stress, bestowing cancer cells with a remarkable resilience against therapies designed to induce lethal damage. This mitophagy-driven defense mechanism enables prostate cancer cells to survive treatment regimens that would otherwise be effective, thus revealing a sophisticated layer of therapeutic evasion.

The implications of these findings are profound. They underscore a fundamental flaw in the current approach to drug design for kinase targets: the assumption that merely inhibiting the catalytic activity of a protein suffices to halt its oncogenic functions. Dr. Warfel emphasizes that the presence of the PIM1 protein itself—irrespective of its enzymatic activity—can sustain drug resistance, signaling a need for therapies that eliminate the protein entirely rather than merely neutralizing its kinase function.

In response to this challenge, the research team previously engineered a novel class of molecules known as proteolysis-targeting chimeras (PROTACs), specifically designed to induce the degradation of the PIM1 protein. Their lead compound, PIMTAC, capitalizes on the cell’s own proteasomal machinery to selectively tag and destroy PIM proteins, rather than simply inhibiting their kinase activity. Laboratory experiments and mouse model studies demonstrate that PIMTAC significantly enhances cancer cell death by increasing oxidative stress and disrupting the HMGB1-mediated survival pathway, outperforming conventional PIM1 inhibitors.

PIMTAC’s capacity to degrade PIM1 addresses both the signaling-dependent and -independent functions of the protein, offering a more comprehensive treatment strategy. By eliminating the kinase-independent survival effects, this approach holds promise for overcoming the persistent issue of drug resistance that hampers the efficacy of current therapies. The data suggest that this novel method could extend beyond prostate cancer to other malignancies where PIM proteins contribute to disease progression, including breast, lung, and various hematologic cancers.

While the development of PIMTAC represents a significant advance, the research remains in its preclinical phase. Challenges such as optimizing systemic delivery of the relatively large PROTAC molecule and improving its tumor-targeting specificity need to be addressed before clinical trials can commence. However, the insights gleaned from these studies reaffirm the importance of in-depth biological exploration of cancer targets, even those that have been the focus of research for many years.

This work also reflects a broader paradigm shift in oncology drug development. Increasing recognition of non-catalytic roles played by kinases and other oncogenic proteins suggests a future where protein degradation technologies might supersede traditional enzyme inhibition. Dr. Warfel envisions a landscape in which cancer therapeutics not only disable protein functions but remove the underlying protein itself, thereby dismantling multiple cancer-supportive mechanisms simultaneously.

Ultimately, this study epitomizes the continuous innovation and relentless inquiry needed to outsmart cancer’s adaptability. By uncovering a concealed survival pathway and offering a way to dismantle it, researchers add a crucial weapon to the anticancer arsenal. For patients battling advanced prostate cancer, particularly those facing the frustrations of treatment resistance, such advances kindle hope for more effective, durable therapies that can translate to improved outcomes and prolonged survival.

The journey from laboratory breakthrough to clinical application involves numerous hurdles, but endeavors like Dr. Warfel’s offer a compelling blueprint for future cancer research. Exploring the nuanced biology of proteins like PIM1 not only deepens scientific understanding but also fuels the creation of revolutionary treatments with the potential to save lives. This study stands as a testament to the power of reexamining established targets with fresh eyes and cutting-edge techniques, underscoring the importance of basic and translational research in reshaping cancer therapy.

As the medical community continues to explore the complexities of tumor biology, the integration of protein-targeting strategies such as PROTACs will likely play an instrumental role in overcoming therapeutic resistance. The PIM1-HMGB1 interaction and its influence on mitophagy highlight how intricate and multifaceted cancer cell survival mechanisms can be. Future investigations will undoubtedly build upon this foundational work, expanding the horizon of possibilities for precise, effective, and personalized cancer treatment modalities.

Subject of Research: Cells

Article Title: Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress

News Publication Date: 27-May-2026

Web References:

• Cancer Letters Article: https://www.sciencedirect.com/science/article/pii/S0304383526003745
• Previous related work: https://www.mdpi.com/2073-4409/11/6/1006

References: DOI: 10.1016/j.canlet.2026.218611

Image Credits: Medical University of South Carolina, Photo by Clif Rhodes

Keywords: Kinase inhibitors, Prostate cancer, Autophagy